IDH2 and neoplasm: The results showed that patients sub‐grouped by tumour grade, IDH mutation, 1p/19q codeletion or MGMT promoter unmethylated status, suffer worse outcome in the high‐risk group in TCGA dataset (Figures 3C–G and S7A).